Northeast Georgia Medical Center - Gainesville

Clinical Trials in Georgia

A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib in Patients with Non-squamous RET Positive Stage IV Non-small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy, A Lung-MAP Treatment Trial
Cancer Type: Lung Cancer

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type: Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer

A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type: Ovarian Cancer

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type: Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial
Cancer Type: Gallbladder Cancer, Unknown Primary

EHR Tool in Assessing Heart Health among Cancer Survivors
Cancer Type: Breast Cancer, Colon/Rectal Cancer, Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Solid Tumor, Unknown Primary

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer, Unknown Primary

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type: Lung Cancer

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Cancer Type: Unknown Primary, Uterine Cancer

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Cancer Type: Lung Cancer

Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer
Cancer Type: Pancreatic Cancer

Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Cancer Type: Prostate Cancer , Unknown Primary

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life